**Aim of the study:** To examine characteristics and treatment patterns of symptomatic neuroendocrine tumors (NETs) patients who received lanreotide Autogel 120 mg (ATG120) administered as part of routine clinical practice.

**Material and methods:** Lanro-NET is a national, multicenter, non-interventional, observational study in the population of adult patients with symptomatic NETs treated with ATG120 for at least three months before inclusion. Data on demographic and clinical characteristics of the population, dosing interval regimen and aspects of administration were collected prospectively during 12 months. Costs were calculated from the perspective of public payer for the year 2014.

**Results:** Fifty-two patients were enrolled in the study. Primary tumors were located predominantly in gastrointestinal tract (51.2%), all tumors were metastatic. The most commonly reported disease symptoms were flushing and diarrhea (55.8% of patients). 86% of patients had undergone surgery, chemotherapy and radioisotope therapy were used in 11.6% and 46.5% of patients, respectively. During the 12-months observation 12 (28%) patients received ATG120 at an extended dosing interval (> 4 weeks), the mean number of days between injections was 31.75 (SD 6.74). The cost of ATG12 was estimated at 4273.17 PLN/patient/month. In all patients ATG120 was administered by nurse, 51.6% of injections in out-patient setting, 48.4% – in hospital.

**Conclusions:** This study presents the current use of ATG120 in the population of Polish NETs patients in a realistic clinical settings. Finding that 28% of patients could be treated with extended dose intervals supports the potential for ATG120 of reducing treatment burden.

**Key words:** neuroendocrine tumors, lanreotide Autogel, clinical study, cost of treatment.

---

**LanroNET, a non-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in Polish patients with neuroendocrine tumors – results of interim analysis**

Ewa Orelowska1, Tomasz Bednarczuk2, Grzegorz Kaminski1, Beata Kos-Kudla1, LanroNET study group*

LanroNET study group: Elżbieta Andrysiak-Mamos (Department of Endocrinology, Metabolism and Internal Diseases, Pomeranian Medical University in Szczecin), Anna Babińska (Department of Endocrinology and Isotope Therapy, Medical University of Warsaw Military Institute of Medicine, Warsaw), Jolanta Bilcharz-Dorniak (Division of Endocrinology, Department of Pathophysiology and Endocrinology, Silesian Medical University, Katowice), Krzysztof Staufl (Department of Endocrinology and Isotope Therapy, Central Clinical Hospital Ministry of Interior in Warsaw), Tadeusz Budlewski (Division of Isotope Therapy, Central Clinical Hospital Ministry of Interior in Warsaw), Bogumila Czartoryska-Artukowicz (Division of Clinical Oncology, Białostockie Oncology Center in Białystok), Jakub Fiszbach (Department of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, Poznan), Danuta Gajser-Perczak (Department of Endocrinology, Świętokrzyskie Oncology Centre in Kielce), Pawel Gut (Department of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, Poznan), Magdalena Londzin-Olesik (Division of Endocrinology, Department of Pathophysiology and Endocrinology, Silesian Medical University, Katowice), Kornelia Hasse-Lazar (Nuclear Medicine and Endocrinology Oncology Department, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch), Barbara Janzar (Nuclear Medicine and Endocrinology Oncology Department, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch), Beata Jurecka-Lubieniecka (Nuclear Medicine and Endocrine Oncology Department, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch), Karolina Kołosińska (Division of Isotope Therapy, Central Clinical Hospital Ministry of Interior in Warsaw), Aldona Kowalska (Division of Endocrinology Świętokrzyskie Oncology Centre in Kielce), Aneta Lebiedzińska (Health Care Ministry of Internal Affairs in Olzysyn, Warmia and Mazury Oncology Centre), Anna Lewczuk (Department of Endocrinology and Internal Medicine Medical University of Gdańsk), Magdalena Przy (Division of Endocrinology, Department of Pathophysiology and Endocrinology, Silesian Medical University, Katowice), Łukasz Obłończyk (Department of Endocrinology and Internal Medicine Medical University of Warsaw), Violetta Rosiek (Division of Endocrinology, Department of Pathophysiology and Endocrinology, Silesian Medical University, Katowice), Anna Sowa-Staszczak (Department of Endocrinology, University Hospital in Krakow), Elżbieta Stefanis (Division of Endocrinology, University Hospital in Krakow), Krzysztof Sworczak (Department of Endocrinology and Internal Medicine, Medical University of Gdańsk), Anhelli Syrenicz (Division of Endocrinology, Metabolism and Internal Diseases, Pomeranian Medical University in Szczecin), Dorota Szymkiewicz (Division of Isotope Therapy, Central Clinical Hospital Ministry of Interior in Warsaw), Ewa Wachula (Health Care Ministry of Internal Affairs in Olzysyn, Warmia and Mazury Oncology Centre), Anna Zemczak (Division of Endocrinology, Department of Pathophysiology and Endocrinology, Silesian Medical University, Katowice)

1 Faculty of Health Sciences The Jan Kochanowski University Kielce, Poland
2 Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Poland
3 Department of Endocrinology and Isotope Therapy, Military Institute of Medicine, Warsaw, Poland
4 Division of Endocrinology, Department of Pathophysiology and Endocrinology, Silesian Medical University, Katowice, Poland

**Introduction**

Neuroendocrine tumors (NETs) are a rare and heterogeneous group of neoplasms that originate from neuroendocrine cell compartments located in numerous different organ systems [1]. Unlike other solid tumors, they are able to over-secrete hormones and other biological substances normally secreted by neuroendocrine cells, resulting in characteristic syndromes. Because of their low incidence, there is a general lack of disease awareness, and prognosis in diagnosed patients varies widely, depending on grade (pro-
Table 1. Crucial studies evaluating the efficacy and safety of Somatuline ATG

| Study                  | Patient population | Intervention                  | Comparator | Design                   | Primary endpoint                                      | Results                                                                 |
|------------------------|--------------------|-------------------------------|------------|--------------------------|-------------------------------------------------------|------------------------------------------------------------------------|
| Ruszniewski (2004) [8] | Patients with NETs with carcinoid syndrome | Lanreotide ATG every 28 days; 90 mg for the first injections, then 60 mg, 90 mg or 120 mg depending on response to treatment | N/A        | Open, dose titration     | Number of diarrhea episodes, flushings and their severity | Good tolerance of treatment, symptoms and biochemical markers reduction |
| Bajetta (2006) [9]    | Patients with well differentiated NETs | Lanreotide ATG 120 mg every 6 weeks | Lanreotide PR 60 mg every 3 weeks | Open, randomised | Tumor markers and tumor size, symptoms assessment between baseline and week 18 | Good efficacy in NETs controlling                                      |
| SymNET (2006) [9]     | NETs with carcinoid syndrome | Somatuline ATG               | N/A        | Open, cross-sectional    | Overall patient satisfaction regarding diarrhea control | 79% of patients reported treatment satisfaction as regards control of diarrhea; 73% were satisfied with flushing control |
| ELECT Vinik (2014) [11]| NETs with carcinoid syndrome | Lanreotide ATG 120 mg every 28 days | Placebo    | Randomised controlled trial, parallel group for 16 weeks, followed by open-label extension | % of days octreotide required to control symptoms (rescue medication) | During initial phase, need for octreotide was less with Somatuline ATG than placebo (% of days in which octreotide was used –33.7% vs. 48.5% in placebo group, \( p = 0.017 \)) |

For patients with hormonally active NETs, with advanced disease, treatment with somatostatin analogues may last for many years. However, a cost evaluation of treatment with lanreotide ATG has so far not been performed. The aim of this study was to examine characterics and treatment patterns of symptomatic NETs patients who received lanreotide ATG 120 mg administered as part of routine clinical practice and to evaluate over the 24 months prospective follow-up resource utilization and costs of the treatment. This type of study provides evidence on the use of a drug in a realistic setting and can be used as a vehicle for addressing multiple post-approval objectives, e.g. optimizing product usage, documenting cost-effectiveness, and identifying best practice. The analysis of dosage regimen data (patients treated with lanreotide ATG 120 mg every 28 days or 42 days or 56 days during a 24-month period) supports better understanding of the cost and efficiency of treatment.

Material and methods

LanroNET is a national, multicenter, non-interventional, observational, prospective (24-month) study, conducted in accordance with the Declaration of Helsinki [12] and the International Ethical Guidelines for Epidemiological Studies, CIOMS, Feb 2008 [13]. This study also followed the recommendations of the International Epidemiological Association Guidelines for the Proper Conduct in Epidemiologic Research (Good Epidemiological Practice, GEP), Nov 2007 [14], and the International Society for Pharmacoepidemiology (ISPE) Good Pharmacoepidemiology Practices (GPP) Guidelines, April 2007 [15]. All patients gave written informed consent before entering the study.

Data were collected in accordance with the standard management of subjects with symptomatic NETs as applied in everyday practice (by particular site). Treatment monitoring, dose adjustment and all other medical decisions were made at the responsible physician’s discretion.
Table 2. Baseline demographic and disease characteristics of the patients (analysed population)

| Variable                          | Population (n = 43) |
|-----------------------------------|---------------------|
| **Mean (SD) age, years**          | 60.1 (9.6)          |
| **Mean (SD) weight, kg**          | 73.3 (16.0)         |
| **Sex**                           |                     |
| Male, n (%)                       | 19 (44.2)           |
| Female, n (%)                     | 24 (55.8)           |
| **Performance status (ECOG-WHO) n (%)** |         |
| 0                                 | 13 (30.2)           |
| 1                                 | 19 (44.2)           |
| 2                                 | 8 (18.6)            |
| 3                                 | 1 (2.3)             |
| NA                                | 2 (4.7)             |
| **Origin of neuroendocrine tumor n (%)** |         |
| Small intestine                   | 22 (51)             |
| Pancreas                          | 7 (16.3)            |
| Colon/rectum                      | 6 (14)              |
| Bronchopulmonary system           | 2 (4.7)             |
| Unknown                           | 6 (14)              |
| **Proliferation grading n (%)**   |                     |
| G1                                | 25 (58.1)           |
| G2                                | 7 (16.3)            |
| G3                                | 3 (7.0)             |
| Not available                     | 8 (18.6)            |
| **Prior treatment for neuroendocrine tumor n(%)** |       |
| Surgery                           | 37 (86)             |
| Somatostatin analogues            | 36 (83.7)           |
| Chemotherapy                      | 5 (11.6)            |
| PRRT                              | 20 (46.5)           |

Results

Characteristics of the population

A total of 57 patients at 13 centers in different Polish regions were screened, and 52 were enrolled in the study. Of those, 9 patients were excluded from the analysis because of missing source data verification (SVD) of enrollment visits (7 patients) and failure in eCRF (2 patients), leaving 43 patients (19 men/24 women) for inclusion for analysis. Mean age in this population was 60.1 (SD 9.6) years. Other demographic characteristics of the study population are summarized in Table 2. According to ECOG (Eastern Cooperative Oncology Group) – WHO performance status criteria, 13 (30.2%), 19 (44.2%), 8 (18.6%), 1 (2.3%) and 2 (4.7%) patients were designated with status 0, 1, 2, 3, and 4, respectively (Table 2).

Primary tumors were located predominantly in the small intestine (51%), 16.3% of NETs occurred in the pancreas, 14% in the colon/rectum, and the bronchopulmonary system was the site of 4.7% of NETs. Primary tumor location was not documented/assessed in 6 patients (14%). All tumors were metastatic; the proportion of patients with 1 site and ≥ 2 sites of metastases was 18.6% and 81.4%, respectively.

The primary tumor could not be evaluated in 12 (27.9%) patients, and there were 2 (4.6%), 11 (25.6%), 12 (27.9%), and 4 (9.3%) tumors representing stages T1, T2, T3, and T4 (N/A in 2 patients; 4.6%). Regional lymph nodes could not be evaluated in 9 (20.9%) patients, in 4 (9.3%) patients regional lymph nodes were not involved, and in remaining patients the degree of regional lymph node involvement was N1 (22 patients), N2 (4 patients), and N3 (1 patients). Distant metastases were present in the majority of patients (n = 38, 88.4%), in 2 (4.7%) patients distant metastases could not be evaluated, and 1 (2.3%) patient had no distant metastases.

Proliferation indices were available for 35 (81.4%) tumors. Of these, 25 were considered well differentiated (G1), 7 moderately differentiated (G2), and 3 poorly differentiated (G3) according to the WHO classification [16].
Chromogranin A (CgA) and 5-hydroxyindoleacetic acid (5-HIAA) were the most frequently assessed pathological markers. Mean (SD)/median (min, max) CgA and 5-HIAA levels for all patients with baseline assessment (n = 38 and n = 25) were 955.9 (2610.1)/449.5 (23, 15532) ng/ml, and 42.9 (55.2)/28.1 (6, 268) µmol/day, respectively.

The most commonly reported symptoms of the disease were flushing and diarrhea (55.8% of patients), and abdominal pain (53.5% of patients). Fatigue was reported in 34.9% of patients, telangiectasia in 32.6%, hyperglycemia in 18.6%. Cushing syndrome and Zollinger-Ellison syndrome were reported in 2.3% and 2.3% of patients, respectively.

Most patients (86%) had undergone previous surgery; the mean time since surgery was 4.3 (SD: 4.0) years. Chemotherapy was used in the past in 11.6% of patients, PRRT in 46.5% of patients. Thirty-eight patients (83.7%) had been treated previously with somatostatin analogues. Among patients with G1 NETs (n = 25) the proportion of patients previously treated with surgery, PRRT, chemotherapy and somatostatin analogues was 96%, 44%, 8% and 100%, respectively, and the mean time since surgery was 3.57 (SD: 2.7) years.

Pharmacotherapy and costs

At enrollment 34 patients (79.1%) were treated with lanreotide ATG 120 mg given every 4 weeks, and 9 patients (20.9%) received lanreotide ATG 120 mg at an extended dosing interval (> 4 weeks): 8 patients every 6 weeks, 1 patient every 8 weeks. During the 12-month prospective phase of the study the mean number of days between injections was 31.75 (SD 6.74), and the number of patients who received lanreotide ATG 120 mg at an extended dosing interval (> 4 weeks) increased to 12 (27.9%). Changes in dosing regimen of lanreotide ATG 120 mg were reported in 3 patients who had the dose frequency extended (from 4 to 5 weeks), in 1 patient treatment was switched from lanreotide ATG 120 mg to octreotide LAR because of temporary lack of lanreotide ATG 120 mg in this site, and 2 patients changed the treatment to PRRT.

The cost of lanreotide ATG 120 mg calculated based on reimbursement status and retail price of lanreotide ATG 120 mg being in force on 1 September 2014 was 4338.52 PLN/patient/month at baseline and 4273.17 PLN/patient/month during the 12 months of the study (Tables 3, 4).

At baseline lanreotide ATG 120 mg was predominantly administered in hospital (n = 29, 67.4%) (Table 5). During the 12-month prospective phase of the study, 51.1% of injections were administered in an out-patient setting, and 48.4% in hospital (Table 6). In all patients lanreotide ATG 120 mg was administered by a nurse.

Discussion

This study presents the current use of lanreotide ATG 120 mg in the population of Polish NET patients in a realistic clinical setting. This is an observational non-interventional study and there are no protocol-driven procedures or treatment patterns. The prospective design reduces recall bias, considered a weakness of retrospective trials. The study population, coming from 13 centers in different Polish regions, represents a wide cross-section of NET patients in our country and seems to be representative.

Interim analysis of results, mostly related to the primary objective of the study – the resource utilization and cost of treatment of symptomatic NET patients in Poland with lanreotide ATG 120 mg, from 12 months of observation, are presented. The demographic and clinical characteristics of the Polish population are, while not identical, at least comparable to those described in NET samples in other European countries [17–21]. Our data are close to most other epidemiological surveys with respect to age and gender of the population. The small intestine was the most pre-

| Table 5. Administration of lanreotide ATG (setting, person, who administer lanreotide ATG) at baseline. |
|---------------------------------------------------|---------------------------------------------------|-----------------|-----------------|-----------------|
| **Person, who administer lanreotide ATG n (%)** | **Total** |
| **Setting of administration** | **Physician** | **Caregiver** | **Patient** | **Nurse** |
| Home | 0 | 0 | 0 | 0 |
| Out-patient setting | 0 | 0 | 0 | 14 (32.6) |
| In-patient setting | 0 | 0 | 0 | 29 (67.4) |
| Total | 0 | 0 | 0 | 43 (100) |

**Table 3. Dosing regimen and cost of lanreotide ATG 120 mg at baseline (n = 43)**

| **Dose Interval (weeks)** | **N. of patients** | **Cost/PLN/month*** |
|---------------------------|-------------------|---------------------|
| **Lanreotide ATG 120 mg** |                   |                     |
| 4                         | 34                | 43                  |
| 6                         | 8                 | 1                   |

Retail and reference price of lanreotide ATG 120 mg – 4683.42 PLN/pack, full reimbursement [Obwieszczenie Ministra Zdrowia z dn. 22 sierpnia 2014 r. (poz.64)] [16]

**Table 4. Dosing regimen and cost of lanreotide ATG 120 mg in the 12-month prospective phase of LanroNET (n = 43)**

| **Dose Interval (weeks)** | **N. of patients** | **Cost/PLN/month*** |
|---------------------------|-------------------|---------------------|
| **Lanreotide ATG 120 mg** |                   |                     |
| 4                         | 31                | 43                  |
| 5                         | 3                 | 1                   |

Retail and reference price of lanreotide ATG 120 mg – 4683.42 PLN/pack, full reimbursement [Obwieszczenie Ministra Zdrowia z dn. 22 sierpnia 2014 r. (poz.64)] [16]
dominant NET location among Polish patients. A high percentage of NETs occurring in the small intestine has also been reported for many European countries, including Italy (24%) [18], Germany (22%) [17], Norway (26%) [20] and Sweden (35%) [19]. In the Polish study, similarly as in the German study [17], two differences from other published series are: the small number of lung tumors and the high percentage of cases of cancer of unknown primary tumor. The percentage of G3 tumors in our study was only 7%, which was lower than that observed in the German population (18%) [17]. This high percentage of poorly differentiated tumors probably does not indicate an unusually high prevalence, as grading available only for one third of the patients in the German study may have been performed preferentially for more malignant tumors, resulting in over-reporting of G3 tumors.

Our study showed that 86% of patients had undergone surgery. In contrast, only 58% of Norwegian patients received primary tumor surgery and 16% received palliative surgery [20], while in Germany surgery was the first treatment in 77.5% of patients [17]. The relatively high percentage of patients treated with PRRT (46.5%) seems to be very specific for the Polish population.

Some limitations of this study need to be considered. The decision on interval duration may in part reflect limitations in funding by the National Health Fund. Interim analysis does not present the effects of treatment, as it is focused on the primary end-points: resource utilization, costs per month and aspects of administration of lanreotide ATG 120 mg. Nevertheless, such effects will need to be presented in the final report.

So far, limited data have been published concerning dosing patterns and cost of somatostatin analogues used for treatment of NET patients in routine clinical practice. The only published pharmacoeconomic data comparing lanreotide versus octreotide in gastro-entero-pancreatic tumors come from the PHARMO Record Linkage System in the Netherlands [21]. A cost-minimization model was used to compare lifetime costs of both drugs used in routine clinical settings. Data for patients receiving outpatient dispensing long-acting lanreotide and octreotide in 2003–2010 were selected from the national database. A total of 92 patients were identified. Stratified by week, 17% of octreotide users received injections every 3 weeks, 67% every 4 weeks, 13% every 5 weeks, and 3% every 6 weeks. In comparison, 88% of lanreotide users received injections every 4 weeks and 13% every 6 weeks. Mean injection intervals were 27 ±8 days for octreotide and 31 ±10 days for lanreotide. This resulted in an average patient cost 7% less with lanreotide than octreotide based on the cost minimization model. In conclusion, this analysis suggested that long-acting lanreotide use reduced costs compared with long-acting octreotide. The driver of cost savings was the longer injection interval with lanreotide during stable treatment for NETs.

In our study, at enrollment 34 patients (79.1%) were treated with lanreotide ATG 120 mg given every 4 weeks, and 9 patients (20.9%) received lanreotide ATG 120 mg at an extended dosing interval (> 4 weeks): 8 patients every 6 weeks, 1 patient every 8 weeks. During the 12-month prospective phase, the mean number of days between injections was 31.75. This is in fact the same mean injection interval as that observed in the PHARMO database. Our study was non-interventional and non-comparable, so data related to octreotide treatment patterns are not available.

The possibility of extending dosing intervals of drugs administered in injections may positively influence patients’ preference for treatment and compliance. A recent study evaluating the efficacy and safety of extended dosing intervals with lanreotide ATG 120 mg in patients with acromegaly previously controlled with conventional doses of octreotide LAR every 4 weeks demonstrated that extending dosing intervals was associated with patient preference over octreotide [22].

The cost of lanreotide ATG 120 mg calculated based on reimbursement status and retail price in force from 1 September 2014 was 4338.52 PLN/patient/month at baseline and 4273.17 PLN/patient/month during the 12 months of the study. This real cost of treatment is lower than the price of lanreotide ATG 120 mg with its wholesale gross price of 4683.42 PLN/pack. Findings that a substantial number of patients with functional NETs are treated with dose intervals longer than 28 days strongly support the potential for lanreotide ATG 120 mg to reduce the treatment burden. These findings are also in accordance with results of the Lano-Study conducted recently among acromegaly patients in Poland, where during the 12-month prospective phase of the study 70 patients (50%) received lanreotide ATG120 at an extended dosing interval [23].

This study was founded by Ipsen Poland sp. z o.o. Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other inter-

### Table 6. Administration of lanreotide ATG (setting, person, who administer lanreotide ATG) during 12-months

| Setting of administration | Physician | Caregiver | Patient | Nurse |
|---------------------------|-----------|-----------|---------|-------|
| Home                      | 0         | 0         | 0       | 0     |
| Out-patient setting       | 0         | 0         | 0       | 174 (51.6) |
| In-patient setting        | 0         | 0         | 0       | 163 (48.4) |

n is the number of injections of lanreotide ATG 120 mg, percentage is the percentage of the total number of injections.
est that is relevant to the subject matter under consideration in this article: Ewa Orlewska has received research funding and/or honoraria from: Ipsen Poland sp. z o.o., Merck sp. z o.o. and Jelfa SA. All other authors declare no competing interests.

References

1. Kulke MH, Benson AB, III, Bergsland E, et al. Neuroendocrine tumors. J Natl Compr Canc Netw 2012; 10: 724-64.
2. National Comprehensive Cancer Network. The NCCN Clinical Practice Guidelines in Oncology (NCCNGuidelines): Neuroendocrine Tumors. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed August 7, 2014.
3. Salazar R, Wiedenmann B, Rindi G, et al. ENETS 2011 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update. Neuroendocrinology 2012; 95: 71-3.
4. Vinik AI, Woltering EA, Warner RP. NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor. Pancreas 2010; 39: 713-34.
5. Bolanowski M, Bednarczuk T, Bobek-Billewicz B, et al. Consensus Conference. Neuroendocrine neoplasms of the small intestine and the appendix – management guidelines (recommended by the Polish Network of Neuroendocrine Tumors). Endokrynol Pol 2013; 64: 480-93.
6. Kos-Kudla B, Blicharz-Dorniak J, Handkiewicz-Junak D, et al. Consensus Conference. Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol 2013; 64: 418-43.
7. Oberg K, Knigge U, Kwekkeboom D, Group E.W.G. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 Suppl 7 vii124-vii130 available from: http://ncbi.nlm.nih.gov/pubmed/22997445.
8. Ruszniewski P, Ish-Shalom S, Wymenga M, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 2004; 80: 244-51.
9. Bajetta E, Procopio G, Catena L, et al. Lanreotide Autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a phase III study. Cancer 2006; 107:2474-81.
10. Ruszniewski P, Caplin M, Valle J, et al. Patient-reported satisfaction with symptom control during lanreotide Autogel/Depot treatment for carcinoid syndrome in gastroenteropancreatic neuroendocrine tumor patients: SymNET, a large multinational cross-sectional observational study. GI Cancers Symposium 2014 Abstract No: 273.
11. Vinik A, Wolin EM, Audry H, et al. ELECT: a phase III study of efficacy and safety of lanreotide Autogel/depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs). GI Cancers Symposium 2014 Abstract No: 268.
12. Declaration of Helsinki, 2008.
13. International Ethical Guidelines for Epidemiological Studies, CIOMS, Feb.2008.
14. International Epidemiological Association Guidelines for the Proper Conduct in Epidemiologic Research (GEP) – Nov 2007.
15. International Society for Pharmacoepidemiology (ISPE) Good Pharmaco Epidemiological Practices (GPP) Guidelines, April 2007.
16. Obwieszczenie Ministra Zdrowia z dn. 22.sierpnia 2014 r w sprawie refundowanych leków, środków specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych. Dziennik Urzędowy Ministra Zdrowia poz.64. http://dzieunikmz.mz.gov.pl/actdetails.html?year=2014&act=64.
17. Ploeckinger U, Kloeppel G, Wiedenmann B, Lohmann R. The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors. Neuroendocrinology 2009; 90: 349-63.
18. Caldarella A, Crocetti E, Paci E. Distribution, incidence, and prognosis in neuroendocrine tumors: a population based study from cancer registry. Pathol Oncol Res 2011; 17: 177-90.
19. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001; 92: 2204-10.
20. Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008; 113: 2655-64.
21. Bezemer ID, Penning FJA, Brulais S, et al. Characteristics of long-acting somatostatin (SSA) use in gastro-entero-pancreatic neuroendocrine (GEP-NET) tumors in the Netherlands. Value in Health 2012; 15: A435.
22. Van der Lely Aj, Negers S, Pronin V. Extended dosing intervals with lanreotide Autogel/Depot 120 mg can be effective in acromegalic patients biochemically controlled with octreotide LAR 10 or 20 mg: the LEAD study. Endocrine Society's 96th Annual Meeting and Expo, June 21–24, 2014 – Chicago, Abstract No: SUN-0621.
23. Orlewska E, Kos-Kudla B, Sowiński J, et al. Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients - results from the prospective 12-month phase of LanroNET. Contemp Oncol (Pozn) 2013; 17: 460-5.

Address for correspondence
Prof. Ewa Orlewska
MD, PhD
Centre for Pharmacoconomics
Kremowa 13
02-969 Warsaw, Poland
e-mail: ewaorlewska@tlen.pl

Submitted: 5.11.2014
Accepted: 13.12.2014